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Type 1 diabetes (T1D) is an autoimmune disease in which a strong inflammatory response
causes the death of insulin-producing pancreatic β-cells, while inefficient regulatory
mechanisms allow that response to become chronic. Ethyl pyruvate (EP), a stable
pyruvate derivate and certified inhibitor of an alarmin–high mobility group box 1 (HMGB1),
exerts anti-oxidant and anti-inflammatory properties in animal models of rheumatoid
arthritis and encephalomyelitis. To test its therapeutic potential in T1D, EP was
administered intraperitoneally to C57BL/6 mice with multiple low-dose streptozotocin
(MLDS)-induced T1D. EP treatment decreased T1D incidence, reduced the infiltration
of cells into the pancreatic islets and preserved β-cell function. Apart from reducing
HMGB1 expression, EP treatment successfully interfered with the inflammatory response
within the local pancreatic lymph nodes and in the pancreas. Its effect was restricted
to boosting the regulatory arm of the immune response through up-regulation of
tolerogenic dendritic cells (CD11c+CD11b−CD103+) within the pancreatic infiltrates and
through the enhancement of regulatory T cell (Treg) levels (CD4+CD25highFoxP3+). These
EP-stimulated Treg displayed enhanced suppressive capacity reflected in increased
levels of CTLA-4, secreted TGF-β, and IL-10 and in the more efficient inhibition of effector
T cell proliferation compared to Treg from diabetic animals. Higher levels of Treg were a
result of increased differentiation and proliferation (Ki67+ cells), but also of the heightened
potency for migration due to increased expression of adhesion molecules (CD11a and
CD62L) and CXCR3 chemokine receptor. Treg isolated from EP-treated mice had the
activated phenotype and T-bet expression more frequently, suggesting that they readily
suppressed IFN-γ-producing cells. The effect of EP on Treg was also reproduced in vitro.
Overall, our results show that EP treatment reduced T1D incidence in C57BL/6 mice
predominantly by enhancing Treg differentiation, proliferation, their suppressive capacity,
and recruitment into the pancreas.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease that develops as a consequence of β-cell
death and subsequent lack of insulin. The cells that infiltrate the pancreatic islets and destroy
β-cells are usually M1 pro-inflammatory macrophages and dendritic cells (DC) that present
autoantigens to CD8+ cytotoxic lymphocytes, IFN-γ-producing Th1 and IL-17-producing Th17
lymphocytes. The opposing components of the immune response are M2 anti-inflammatory
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macrophages, as well as tolerogenic DC that enable activation of
regulatory T lymphocytes (Treg) (1). The balance between pro-
inflammatory and regulatory cells is a common target for new
experimental T1D therapeutics, for example, ethyl pyruvate (EP).
This is a stable pyruvate derivative that possesses anti-oxidant
and anti-inflammatory properties. It is a genuine inhibitor of
highmobility group box 1 (HMGB1), a protein that, like histones,
binds DNA and regulates transcription (2). More importantly,
HMGB1 can be secreted by monocytes, macrophages and
dendritic cells and can act as an alarmin to promote
inflammation and generation of reactive oxygen species (ROS)
and reactive nitrogen intermediates (RNI) (3, 4). Either through
inhibition of HMGB1 or interaction with other still unknown
molecules, EP has been found beneficial in the treatment of
various inflammatory disorders, including myocardial ischemia-
reperfusion injury (5), sepsis (6), pancreatitis (7), colitis
(8), inflammatory arthritis (9), and experimental autoimmune
encephalomyelitis (10). Thorough analysis of EP’s mechanism
of action in the autoimmune process that targets CNS suggests
that EP ameliorated the symptoms of experimental autoimmune
encephalomyelitis through inhibition of HMGB1 secretion from
microglia/macrophages (10, 11). The activity of phagocytic cells
(ROS production and antigen presentation properties) and Th
cells (IFN-γ and IL-17 production) was significantly impaired by
the action of EP (10, 11). The effects of EP include more than
only the inhibition of the pro-inflammatory response; EP also
boosts the regulatory component of immunity, as recent findings
indicate that EP promotes the differentiation of tolerogenic DC
(tolDC) in vitro (unpublished data). However, there are no data
on the possible effect of EP on Treg.
So far, EP has been mostly used to treat the secondary
effects that diabetes and the resulting hyperglycemia have on
the retina (12), kidneys (13), or liver (14). Having in mind that
HMGB1 enhances the progression of T1D in NOD mice (15),
the application of EP might prove beneficial for the treatment of
T1D.
MATERIAL AND METHODS
Animals
C57BL/6 mice were kept at the animal facility at the Institute
for Biological Research “Sinisa Stankovic,” under standard
conditions with free access to food and tap water. All
experimental procedures were approved by the Ethic Committee
at the Institute for Biological Research “Sinisa Stankovic” (App.
No 01-11/17 - 01-2475) in accordance with the Directive
2010/63/EU.
T1D Induction and EP Treatment
T1D was induced in 2 months old male C57BL/6 mice using
multiple low doses of streptozotocin (MLDS) that were given
intraperitoneally for 5 consecutive days. Streptozotocin (STZ) (40
mg/kg bw, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in
cold 0.1M citrate buffer (pH 6) just prior to administration. Ethyl
pyruvate (EP) (100 mg/kg bw, Sigma-Aldrich) was dissolved
in Hartmann’s solution (Hemofarm A.D., Vršac, Serbia) and
administered intraperitoneally, starting from the first dose of STZ
for 9 days in total. STZ and EP injections were given 3 h apart.
MLDS-treated group also received the diluent in equal volume.
Mice were monitored for the development of hyperglycemia by
weekly measurements of blood glucose levels, using a glucometer
(Sensimac, IMACO GmbH, Lüdersdorf, Germany). Animals
were considered hyperglycemic if their blood glucose level was
higher than 11 mmol/l in non-fasted animals. The presence of
ketones in urine (as an indirect measure of high glucose levels)
was detected by URiSCAN test strips (YD Diagnostics, Kyunggi-
Do, South Korea). Ex vivo analyses were performed between the
11th and the 15th day after the first STZ injection.
Histological Analysis
To assess the incidence of inflammatory changes and the
degree of islet cell destruction, pancreata were collected on the
35th day after the first STZ injection, embedded in paraffin,
sectioned (5µm thick sections, at least 200µmbetween sections),
stained with Mayer’s hematoxylin (Bio-Optica, Milan, Italy) and
examined by light microscopy (Zeiss Imager Z1, AXIO, Carl
Zeiss Meditec AG, Oberkochen, Germany). Insulitis scoring was
performed by examining at least 20 islets per pancreas and graded
in a blinded fashion as follows: grade 0, intact islet; grade 1,
peri-islet infiltrate; grade 2, heavy intra-islet infiltrate. Results are
expressed as a percentage of graded islets out of the total number
of islets.
Immunohistochemical staining was performed on pancreatic
sections collected on the 15th day after the first STZ
injection in the following manner. To assess the presence
of insulin, PE conjugated rabbit anti-mouse insulin antibody
(1:400, Cell Signaling Technology, Danvers, MA, USA) was
used, while counterstaining was carried out with Hoechst
33342 dye (2 µl/ml, ChemoMetec, Allerød, Denmark). For
the negative control, rabbit anti-goat IgG-biotin (Vector
Laboratories, Burlingame, CA, USA) coupled with streptavidin-
PE (ThermoFisher Scientific, Waltham, MA, USA) was used.
Image acquisition (20×) was performed using an AxioVision
microscope (Carl Zeiss Meditec AG, Germany). The presence
of insulin in the pancreatic islets was determined with Fiji,
an open-source distribution of ImageJ software for biological
image analysis (16). The acquired images were converted to gray
scale, and fluorescence intensity was quantified by measuring
the mean gray value, which represents the sum of gray values
of all pixels in the selection divided by the number of pixels.
For HMGB1 assessment, anti-mouse HMGB1 antibody (1:500,
Invitrogen, Carlsbad, CA, USA) was paired with a secondary
HRP conjugated anti-mouse IgG (1:1,000, Invitrogen), incubated
with ExtrAvidin peroxidase (1:10, Sigma-Aldrich) and finally
stained with DAB chromogen solution (1:50, DakoCytomation,
Glostrup, Denmark), while counterstaining was carried out with
hematoxylin. For the negative control, HRP conjugated anti-
mouse IgG-treated sections were used. The presence of HMGB1
in pancreatic islets was measured in the following way. Pancreatic
islets were photographed at the magnification of 20×, and
HMGB1 positive regions were determined using the Color Picker
Threshold Plugin within Icy, open-source bioimage processing
software (17). Using a representative pancreatic section, at least
15 positive colors (shades of darker brown) and 15 negative
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colors (blue, white and light brown) were selected as standard
recognition patterns. Those were then applied to all pancreatic
sections to differentiate between stained and unstained tissue
regions. The presence of HMGB1 in pancreatic islets was
expressed as a relative percentage of the HMGB1-positive islet
area divided by the area of the whole pancreatic islet.
Cell Isolation
Spleen and pancreatic lymph node (PLN) cells were obtained by
passing the tissue through the cell strainer (40µm) and after
removal of the erythrocytes by RBC Lysis Buffer (eBioscience,
San Diego, CA, USA). Pancreatic infiltrates were obtained by
collagenase type V (Sigma-Aldrich) digestion of the pancreatic
tissue (from which lymph nodes were previously removed).
Tissue was cut into small pieces and shaken for 10min at 37◦C.
Digests were passed through a 20µm cell strainer and washed
several times in Hank’s balanced salt solution. The cells were
finally resuspended in RPMI 1640 supplemented with 5% fetal
calf serum (FCS), 1% penicillin and streptomycin (all from PAA
Laboratories, Pasching, Austria), 2mM L-glutamine and 25mM
HEPES. CD4+CD25−, CD25+ or CD25− cells were marked
for separation from the spleen, cervical and mesenteric lymph
node cell suspension by incubation with biotin conjugated anti-
mouse CD4 (1:60) or biotin conjugated anti-mouse CD25 (1:100)
antibodies (both from eBioscience). They were then resuspended
in cold magnetic bead buffer (PBS+0.5% BSA+2mM EDTA)
containing BD IMagTM Streptavidin Particles Plus–DM (1:20,
BD Biosciences, Bedford, MA, USA). The appropriate cells were
purified by placement in a BD IMagTM Cell Separation Magnet
(BD Biosciences), 3× for 8min, and finally resuspended in a T
lymphocyte medium–RPMI 1640 supplemented with 10% FCS,
1% penicillin and streptomycin, 0.02mM Na-pyruvate, 5µM
β-mercaptoethanol, 2mM L-glutamine, and 25mMHEPES.
Detection of Extracellular and Intracellular
Markers by Flow Cytometry
Surface molecules were detected on viable cells dispersed
in PBS+1% BSA. The following antibodies were used: anti-
mouse CD4 PerCP-Cyanine5.5 (rat IgG2a,κ), anti-mouse CD4-
FITC (rat IgG2b,κ), CD4-APC (rat IgG2b,κ), anti-mouse CD8-
PE (rat IgG2a,κ), anti-mouse B220-FITC (rat IgG2a,κ), anti-
mouse CD19-PE-Cy5 (rat IgG2a,κ), CD11c-PE-Cy5 (Armenian
hamster IgG), F4/80-FITC (rat IgG2a,κ), CD25-Alexa Fluor R©
488 (rat IgG1,λ), CD25-PE (rat IgG1,λ), CD101-PE (rat
IgG2a,κ), CD62L-PE-Cy7 (rat IgG2a,κ), CD206-PE (rat IgG2b,κ),
CD127 APC-eFluor 780 (rat IgG2a,κ), MHC II-FITC (rat
IgG2b,κ), CD357 (GITR)-FITC (rat IgG2b,κ), CD80-PE-Cy5
(Armenian hamster IgG), CD86-PE-Cy5 (rat IgG2a,κ), CD103-
FITC (Armenian hamster IgG), CD5-FITC (rat IgG2a,κ), CD11a-
FITC (rat IgG2a,κ), CD40-PE (Armenian hamster IgM,κ),
anti-rat IgG-PE (all from ThermoFisher Scientific), CD11b
(rat IgG2b,κ) (BD Biosciences), PD-1 (rat IgG2a,κ) (Abcam,
Cambridge, MA, USA). The staining was performed for
30min at 4◦C. Regulatory T cells (Treg) were detected by
Mouse Regulatory T cell Staining Kit (FoxP3) according to
the manufacturer’s instructions (eBioscience). For intracellular
cytokine staining, cells were stimulated with Cell Stimulation
Cocktail (plus protein transport inhibitors) (1:500, eBioscience)
for 4 h. Cells were fixed in 2% paraformaldehyde, permeabilized
and stained with the following antibodies: anti-mouse IFN-γ-PE
(rat IgG1,κ), IL-4-PE (rat IgG1,κ) (both from eBioscience) or IL-
17-PE (rat IgG1,κ) (BD Biosciences). Isotype-matched controls
were included in all experiments (eBioscience). For Ki67-
FITC (goat polyclonal antibody) (SantaCruz Biotechnology, San
Diego, USA), T-bet-PE (mouse IgG1,κ) and RORγT-PE (rat
IgG1,κ) (eBioscience) antibodies, cells were permeabilized using
the same protocol as for FoxP3 (Treg) detection. Cells were
acquired on Partec CyFlow Space by FlowMax software (Partec,
Görlitz, Germany) or by FACSCalibur and BD FACSAria III
(BD Biosciences) and analyzed by FlowMax (Partec) or FlowJo
software (Treestar, Ashland, OR, USA). Cells were first gated
on live cells (empirically determined) and then further gated
appropriately to the required analysis.
Measurement of Intracellular Nitric Oxide
and Reactive Oxygen Species
4-Amino-5-methylamino-2′7′-difluoro-fluorescein diacetate
(DAF-FM diacetate; Molecular Probes, Leiden, The Netherlands)
was used as an indicator of intracellular nitric oxide (NO).
Briefly, pancreatic infiltrates were incubated with 2µMDAF-FM
diacetate for 1 h at 37◦C, washed, and then incubated for
15min at 37◦C in phenol red- and serum-free RPMI-1640 for
the completion of de-esterification of intracellular diacetates.
The cells were than washed and resuspended in PBS. Green
(FL1) fluorescence emission was measured with Partec CyFlow
Space and analyzed by FlowMax software. Dihydrorhodamine
123 (DHR) was used to reactive oxygen species (ROS). After
isolation, cells were immediately exposed to DHR (5µM) for
20min at 37◦C. After being washed, the cells were analyzed
with the flow cytometer. The mean fluorescence intensity (MFI)
as a measure of intracellular production of NO and ROS was
measured in the macrophage gate (higher SSC level compared to
the lymphocyte gate).
Immunoblot
Ex vivo isolated cells (5× 106) from PLN or pancreatic infiltrates,
purified CD25+ cells (5× 105) or in vitro cultured CD4+CD25−
(5 × 106) were lysed in the buffer containing 62.5 mmol/l
Tris–HCl (pH 6.8 at RT), 2% SDS, 10% glycerol, 50 mmol/l
DTT, 0.01% bromophenol blue (all from Sigma-Aldrich).
All samples were subjected to electrophoresis on 12% SDS–
polyacrylamide gel (SDS–PAGE). After electro-transferring the
samples to polyvinylidene difluoride membranes at 5 mA/cm2,
using a semi-dry blotting system (Semi-Dry Transfer Unit, GE
Healthcare, Buckinghamshire, England), the membranes were
blocked with PBST (PBS+0.1% Tween-20, Sigma-Aldrich)+5%
BSA and probed with specific antibodies dissolved in PBST+1%
BSA. Secondary antibodies for anti-mouse CTLA-4 (l:1,000,
Invitrogen) were FITC conjugated anti-armenian and syrian
hamster IgG cocktail (1:1,000, BD Biosciences) and HRP
conjugated anti-mouse IgG (1:5,000, Invitrogen), for anti-mouse
IL-10 (l:600, eBioscience) or anti-mouse IL-2 (l:500, eBioscience)
it was HRP conjugated anti-rat IgG (1:5,000, eBioscience), and
for anti-mouse HMGB1 (1:1,500, Invitrogen) or anti-mouse
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β-actin (1:1,000, Sigma-Aldrich) it was HRP conjugated anti-
mouse IgG (1:5,000, Invitrogen). Detection was performed by
using Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Billerica, MA, USA), while photographs were made
by X-ray films (Kodak, Rochester, NY, USA). Densitometry
was performed with Scion Image Alpha 4.0.3.2 (Scion
Corporation, Frederick, MD, USA), and the production of
specific proteins was expressed relative to the production
of β-actin.
In vitro Suppression Assay and
Transmigration Assay
For the suppression assay, CD4+CD25− cells isolated from either
EP-treated or diabetic animals were first incubated with 2µM
CFSE (Invitrogen) for 20min at RT and 5min at 37◦C, washed
and resuspended in the T lymphocyte medium. A U-bottom 96-
well plate (Sardstedt, Numbrecht, Germany) was coated with
anti-mouse CD3 (1µg/ml, eBioscience), and an equal number of
purified CD4+CD25− cells (25 × 103) was placed in each well.
CD25+ cells were then added in a series of dilutions, starting
from 25 × 103 cells per well, and continuing to a 2×, 4×, 8×,
and 16× lesser number of cells. Certain wells contained only
CD4+CD25− cells, as control. The cells were also stimulated
by the addition of anti-mouse CD28 (1µg/ml, eBioscience) to
the T lymphocyte medium. After 3 days of cultivation, the
cells were washed, resuspended in PBS and analyzed by flow
cytometry.
For the transmigration assay, a special chemotaxis system
was used (ChemoTX System, Neuro Probe Inc., MD, USA).
CD25+ or CD25− cells isolated from either EP-treated or diabetic
animals (105 cells in 50 µl) were placed above a membrane
and their migratory abilities were tested, either toward isolated
pancreatic islets [isolation described in (18)], medium containing
CXCL12 (10 ng/ml, Gibco, ThermoFisher Scientific), or plain
medium as control. After 4 h, the number of cells that migrated
through the membrane and into the wells was determined
by LUNA-II
TM
Automated Cell Counter (Logos Biosystems,
Gyeonggi-do, South Korea).
In vitro Th Differentiation Assay
CD4+CD25− cells (5 × 106) isolated from untreated healthy
animals were stimulated in an adequate manner for the purpose
of Th cell differentiation. All cells received stimuli from plate-
bound anti-CD3 (1µg/ml) and soluble anti-CD28 antibodies
(1µg/ml) (both from eBioscience). For Th1 differentiation
the cells were additionally stimulated with IL-12 (20 ng/ml,
R&D Systems, Minneapolis, MN, USA) and anti-IL-4 antibody
(10 ng/ml, eBioscience), for Th17 differentiation the cells were
stimulated with TGF-β (10 ng/ml, R&D Systems) and IL-6
(10 ng/ml, R&D Systems), while for Treg differentiation the cells
were stimulated with either TGF-β (2 ng/ml) and IL-2 (10 ng/ml)
(both from R&D Systems) (complete stimulation), or only with
IL-2 (incomplete stimulation). EP (125µM) was administered
24 h after the beginning of the culture, and after 4 more days of
cultivation the cells were analyzed for the presence of certain Th
subsets by flow cytometry as described above.
ELISA
Splenocytes were cultured in the presence of LPS (100 ng/ml) for
48 h and cytokine concentration in cell culture supernatants was
determined by sandwich ELISA using MaxiSorp plates (Nunck,
Rochild, Denmark) and anti-mouse paired antibodies according
to the manufacturer’s instructions. Supernatants from previously
described in vitro differentiation experiments were also collected
after 5 days of cultivation. Samples were analyzed in duplicate
for murine TNF, IL-1β, and TGF-β (eBioscience) and absorbance
was measured by LKB microplate reader (LKB Instruments,
Vienna, Austria) at 450 and 570 nm. A standard curve created
from the known concentrations of appropriate recombinant
cytokines was used to calculate concentration values of measured
cytokines.
Statistical Analysis
Data are presented as mean ± SD. The presented results are
representative of four repeated experiments with comparable
results. The significance of differences between groups was
determined by two-tailed Student’s t-test. In addition, for the
analysis of the results with considerable deviations a Mann-
Whitney non-parametric test was used since it produced more
stringent p. The usage of this test is specified in the appropriate
figure legends. Differences are regarded as statistically significant
if p < 0.05. Statistical analyses were performed using GraphPad
Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
The Effect of EP on T1D Development
In order to estimate the effect of EP on T1D development
in C57BL/6 mice, EP was applied prophylactically for 9 days
starting from the first dose of STZ (Figure 1A). In contrast to the
control mice that developed hyperglycemia on the 14th day, mice
treated with EP had a significantly lower incidence of diabetes
(Figure 1B). Also, the number of islets with mononuclear
infiltrates (counted on the 35th day from the beginning of
the experiment) was lower in EP-treated mice compared to
diabetic mice (Figures 1C–E), while the presence of functional
insulin+ β-cells was higher and similar to that in healthy
islets (Figures 1F–I). Isotype staining for insulin is presented
in Figure S1A. Since there is evidence of higher expression of
HMGB1 in β-cells of NOD mice that develop spontaneous T1D
(15), we measured the expression of HMGB1 in the β-cells of
mice treated with MLDS. Compared to healthy, untreated mice,
HMGB1 expression in diabetic mice was significantly higher,
and EP-treatment successfully suppressed the observed change
(Figures 1J–M). Background staining is presented in Figure S1B.
In addition, throughout the examination period mice treated
with EP gained weight normally (data not shown) and only 14%
of EP-treated mice had ketones in urine compared to 71% of
diabetic ones (Figure 1N).
The Influence of EP Treatment on Innate
Antigen-Presenting Cells
Ex vivo analysis of cells from spleen, PLN and pancreatic
infiltrates showed that EP treatment did not change the number
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FIGURE 1 | The effect of EP on T1D development. (A) Diagram of diabetes induction, EP treatment and diabetes monitoring by weekly measurements of blood
glucose levels. (B) T1D incidence presented as a proportion of C57BL/6 mice with glycemia higher than 11 mmol/L. (C) The proportion of pancreatic islets without
immune cell infiltrates, with infiltrates surrounding the islets (peri-insulitis) and with infiltrates within the islet (insulitis). Representative images of pancreatic islets from
MLDS-treated mice (D) or EP-treated mice (E), stained with hematoxylin. (F) Insulin expression was determined by analyzing fluorescence intensity with Fiji software.
Representative images of pancreatic islets from a control healthy animal (G), MLDS-treated mice (H) or EP-treated mice (I) stained for insulin visualization (red) and
with Hoechst 33342 (nucleus – blue). (J) HMGB1 expression within pancreatic β-cells was determined using the Color Picker Threshold Plugin within Icy software.
Representative images of pancreatic islets from a control healthy animal (K), MLDS-treated mice (L) or EP-treated mice (M) stained for HMGB1. (N) The proportion of
mice with ketones in urine. All groups consisted of 7-10 animals. *p < 0.05 represents a statistically significant difference between MLDS+EP-treated compared to
MLDS-treated mice.
of F4/80+ macrophages (Figure S2A), while it significantly
affected the proportion of dendritic cells (Figure 2A). More
precisely, the proportion of CD11c+ DC was significantly
down-regulated in PLN, while their number was simultaneously
increased within the pancreatic infiltrates (Figure 2A).
To explore whether EP changed the ratio between pro-
inflammatory M1 and anti-inflammatory M2 macrophage
subsets, we detected F4/80+CD40+ M1 and F4/80+CD206+ M2
macrophages in the pancreatic infiltrates. The results indicate
that EP had no impact on either of the examined macrophage
Frontiers in Immunology | www.frontiersin.org 5 January 2019 | Volume 9 | Article 3130
Koprivica et al. Ethyl Pyruvate Prevents Autoimmune Diabetes
FIGURE 2 | The influence of EP on innate antigen-presenting cells. The proportion of all cells, isolated from the spleen, pancreatic lymph nodes (PLN) or pancreatic
infiltrates, was measured by flow cytometry. (A) The proportion of CD11c+ dendritic cells, along with representative dot plots. (B) The proportion of tolerogenic DC
(CD11c+CD11b−CD103+), along with representative dot plots (first gated on live CD103+ cells, followed by the gate on CD11c+CD11b−). Statistical analysis for
CD11c+ and tolerogenic DC was performed by Mann-Whitney non-parametric test. (C) Proportion of IL-10+ cells within MHC II+ population, along with
representative dot plots. Secretion of IL-1β (D) and TNF (E) from LPS-treated splenocytes cultured ex vivo for 48 h and measured by ELISA. All measurements were
performed on samples from at least 7 animals per group. *p < 0.05 represents a statistically significant difference between cells of MLDS+EP compared to those of
MLDS-treated mice.
subsets (Figure S2B). However, it did increase the proportion
of CD11c+CD11b−CD103+ tolerogenic DC in the pancreatic
infiltrates (Figure 2B). These cells seemed to migrate from PLN
to the pancreas, since their number was reduced in the nodes after
EP treatment (Figure 2B).
To examine the function of antigen-presenting cells, we
measured their ability to produce NO and ROS. Despite being
an anti-oxidant, EP did not affect the production of NO or
ROS in phagocytic cells within the pancreas (Figure S2C).
Also, EP did not influence cells’ antigen presentation capacity
since the expression of co-stimulatory molecules CD80 and
CD86 remained the same on MHC class II+ cells after EP
treatment (Figure S2D). However, EP significantly stimulated
the suppressive function of MHC class II+ cells since the
production of IL-10 in these cells was up-regulated (Figure 2C).
Accordingly, when analyzing LPS-stimulated splenocytes, we
found that cells isolated from EP-treated mice produced lower
amounts of IL-1β (Figure 2D) compared to cells isolated from
diabetic mice, while the secretion of TNFwas similar (Figure 2E).
The Effect of EP on Adaptive Immunity in
Diabetic Mice
Treatment with EP did not significantly change the proportion of
CD4+, CD8+ or B lymphocytes in the spleen, PLN or pancreatic
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FIGURE 3 | Phenotypic analysis of adaptive immune cells after EP treatment. All cell proportions were measured by flow cytometry. (A) The proportion of Th (CD4+),
cytotoxic lymphocytes (CD8+) or B lymphocytes (B220+ or CD19+) in spleen, PLN or pancreatic infiltrates. (B) The proportion of activated cytotoxic lymphocytes
(CD8+CD44+) in the pancreatic infiltrates. (C) The proportion of regulatory B cells (CD19+CD5+ IL-10+) within PLN and pancreatic infiltrates. The proportion of Th
subsets: Th1 (CD4+ IFN-γ+), Th2 (CD4+ IL-4+), Th17 (CD4+ IL-17+) and Treg (CD4+CD25high) within the spleen (D), PLN (E), and pancreatic infiltrates (F) of MLDS
or MLDS+EP-treated mice. Representative dot plots for CD4+CD25high on the right hand side. All measurements were performed on samples from 7 animals per
group. *p < 0.05 represents a statistically significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
infiltrates, except for the reduction in B lymphocytes in PLN
(Figure 3A). Further insight into CD8+ activity revealed that
these cells were similarly activated in both diabetic and EP-
treated mice (Figure 3B). As for B lymphocytes, the proportion
of their regulatory subset (Breg, CD19+CD5+IL-10+) was the
same between the groups both in PLN and in the pancreatic
infiltrates (Figure 3C). All gating strategies and representative
dot plots are shown in Figures S3A–F. After examining the
Th subsets (Figures 3D–F), we found that the proportion of
CD4+CD25high cells (Treg) was up-regulated after EP treatment
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FIGURE 4 | Phenotypical characterization of Treg after EP treatment. (A) Proportion of Treg (CD4+CD25highFoxP3+) within PLN and pancreatic infiltrates, along with
representative dot plots (first gated on live FoxP3+ cells, followed by the gate on CD4+CD25high). (B) The proportion of Treg within PLN that express GITR and are
negative for CD127, along with the representative dot plots (first gated on live CD127−GITR+ cells, followed by the gate on CD4+CD25high). All measurements were
performed on samples from at least 7 animals per group. Statistical analysis was performed by Mann-Whitney non-parametric test. *p < 0.05 represents a statistically
significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
in all tested compartments. Since the most convincing effect
of EP was exerted on Treg, further analysis was focused on
Treg function within the local pancreatic environment. Gating
strategies for Th1, Th2, and Th17 and representative dot plots
are shown in Figures S4A–C.
In vivo EP Effect on Treg Function
To describe the phenotype of Treg in more detail, the
expression of FoxP3 (signature transcription factor of Treg),
GITR (glucocorticoid-induced tumor necrosis factor receptor,
a marker of naturally occurring Treg) and CD127 (α subunit
of IL-7 receptor that is absent on Treg) was determined
within CD4+CD25high cells. The results indicate that EP
increased the number of CD4+CD25highFoxP3+ cells in PLN
and pancreatic infiltrates (Figure 4A). Also, the proportion
of CD4+CD25highCD127−GITR+ cells was increased after EP
treatment (Figure 4B). The expression of Treg markers FoxP3,
GITR, PD-1 per cell did not differ between the groups
(Figure S5A), while the expression of cytotoxic T-lymphocyte
antigen 4 (CTLA-4) in CD25+ cells from EP-treated mice
was significantly increased (Figure 5A). EP’s effect on their
suppressive function was also manifested through a higher
proportion of TGF-β+ Treg in EP-treated animals (Figure 5B),
as well as through higher production of IL-10 in purified CD25+
cells (Figure 5C) and pancreatic infiltrates (Figure 5D). These
data suggest that EP enhances Treg suppressive activity, which
was confirmed in an ex vivo suppression assay (Figures 5E,F).
Compared to CD25+ cells isolated from diabetic mice, cells
from EP-treated mice were more potent in inhibition of CFSE-
measured proliferation of CD4+CD25− T effector cells. Overall,
these results suggest that EP promoted Treg suppressive function
through enhancing their capacity for effector T cell inhibition,
both through cell-to-cell contact and secreted anti-inflammatory
cytokines.
In vivo EP Effect on Treg Differentiation
and Proliferation
The increased proportion of Treg found in both PLN and
pancreatic infiltrates after EP treatment could be attributed
either to increased de novo differentiation from naïve CD4+
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FIGURE 5 | Functional characterization of Treg after EP treatment. (A) CTLA-4 protein expression in CD25+ cells purified from the pool of lymphoid tissues,
normalized to the expression of β-actin, along with the representative blot. (B) The proportion of TGF-β-expressing cells within Treg, along with representative dot
plots. (C) IL-10 protein expression in CD25+ cells purified from a pool of lymphoid tissues, normalized to the expression of β-actin, along with the representative blot.
(D) The proportion of IL-10-expressing Treg within pancreatic infiltrates, along with representative dot plots. (E) The level of inhibition of effector T cell
(Teff–CD4+CD25−) proliferation after co-culture with Treg (CD4+CD25+) cells purified from a pool of lymphoid tissues of MLDS or MLDS+EP-treated mice.
Proliferation was measured after 72 h of incubation by CFSE dilution (in Teff). (F) Proportion of divided Teff, or Teff cultured in the presence of Treg (1:1 ratio).
Representative dot plots are given below. All measurements were performed on samples from 7 animals per group. *p < 0.05 represents a statistically significant
difference between cells of MLDS+EP compared to those of MLDS-treated mice.
cells or to the proliferation of existing ones. For peripheral
differentiation of Treg, CD4+ cells require IL-2 and TGF-β
in their surroundings (19). Although the presence of IL-2 in
PLN stayed the same (Figure 6A), the proportion of TGF-β+
non-Treg cells was significantly elevated after EP administration
(Figure 6B), suggesting that EP enhanced the TGF-β-mediated
signaling pathway for enhanced Treg differentiation. However,
it seemed that apart from differentiation, EP influenced Treg
proliferation as well, judging by the increased number of Ki67+
Treg in the pancreatic infiltrates of EP-treated mice compared to
those isolated from diabetic mice (Figure 6C).
In vivo EP Effect on Treg Migration
Since the proportion of Treg was increased after EP treatment,
the next step was to investigate their migratory capacities. In
addition to the observed increased proliferation, the higher
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FIGURE 6 | The effect of EP on Treg differentiation and proliferation in vivo. (A) IL-2 protein expression in PLN, along with the representative blot. (B) The proportion of
non-Treg producers of TGF-β in the pancreatic infiltrates, along with representative dot plots (first gated on live non-CD25high cells, followed by the gate on TGF-β+).
(C) The proportion of proliferating Treg (CD25highKi67+) in PLN and pancreatic infiltrates. Representative dot plots (first gated on live CD25high cells, followed by the
gate on Ki67+) for pancreatic infiltrates are shown. All measurements were performed on samples from 7 animals per group. *p < 0.05 represents statistically
significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
proportion of Treg might also result from their increased
migration to the site of inflammation. We detected a higher
expression of CD11a (subunit of LFA-1—integrin that drives
cells from blood to tissues) and L-selectin (CD62L—adhesion
molecule that enables transmigration) (Figure 7A) on Treg
isolated from EP-treated mice, as well as an increased number of
chemokine receptor CXCR3+ Treg (Figure 7B). The proportion
of CXCR5+ Treg was the same between the groups (Figure S6A).
These observations suggest that these cells migrated to the
pancreas more readily in EP-treated mice than Treg from
diabetic mice. This was confirmed in an ex vivo transmigration
assay, in which CD25+ cells isolated from EP-treated mice
migrated more efficiently toward pancreatic islets or toward a
CXCL12 concentration gradient, compared to Treg isolated from
diabetic mice (Figure 7C). Finally, EP increased the proportion
of Treg that carried the CD103+ receptor in the pancreatic
infiltrates (Figure 7D), while their proportion was similar in
PLN of both diabetic and EP-treated mice (Figure 7D and
Figure S6B) suggesting increased retention of Treg at the site of
inflammation (20).
The Effect of EP on Treg Activation and
Affinity for Th1 or Th17 Suppression
A higher proportion of Treg from EP-treated mice was
CD44+, suggesting that they became activated (Figure 8A)
and were able to inhibit the activation of effector Th cells
(CD4+CD25med) (Figure 8B). Induced peripheral Treg might
express transcription factors such as T-bet or RORγT and
these cells are thought to specifically inhibit effector T cell
population, Th1 and Th17, respectively. Seemingly, in the
pancreatic infiltrates EP significantly up-regulated the T-bet+
Treg population (Figure 8C), while the proportion of effector
T-bet+CD25med cells was reduced (Figure 8D). However, the
proportion of RORγT+ Treg and effector RORγT+CD25med was
similar in both groups (Figures 8E,F). The expression of T-bet
or RORγT per cell did not differ upon EP treatment (data not
shown).
In vitro EP Effect on Treg Differentiation
Naïve CD4+CD25− cells were stimulated in vitro through
their TCR in the presence of adequate cytokines or antibodies
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FIGURE 7 | The effect of EP on Treg migratory abilities. (A) CD11a and CD62L expression on Treg within PLN, measured by mean fluorescence intensity (MFI).
Representative histograms are shown. (B) The proportion of CXCR3+ cells within activated Th cells (CD4+CD25med) or within Treg (CD4+CD25high) from PLN.
Representative dot plots show the first gate on either live CD4+CD25med or live CD4+CD25high cells, followed by the gate on CXCR3+. (C) Migration of CD25+ cells
purified from a pool of lymphoid tissues of MLDS or MLDS+EP-treated mice in a chemotaxis assay toward pancreatic islets or CXCL12 (10 ng/ml). (D)
CD25highCD103+ proportion within PLN and pancreatic infiltrates. Representative dot plots for pancreatic infiltrates are shown. All measurements were performed on
samples from 7 animals per group. *p < 0.05 represents a statistically significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
that drive the differentiation of Treg, Th1 or Th17 cells. The
addition of EP 24 h after the initial stimulation significantly
promoted the differentiation of Treg, while the proportion of
de novo differentiated Th1 and Th17 cells did not change
compared to the cells cultured without EP (Figure 9A). The
expanded Treg expressed PD-1, GITR and CTLA-4 surface
markers (Figure 9B), but the levels of expression per cell did
not differ compared to Treg developed without EP (data not
shown). EP also stimulated Treg in vitro differentiation in
the absence of TGF-β (incomplete stimulation) (Figure 9C),
suggesting that EP might have stimulated, at least partly, the
intracellular signaling events that mimicked the TGF-β trigger.
Finally, EP stimulated IL-10 production in the CD4+ cultures
exposed to the complete Treg stimulation (Figure 9D). These
data suggest that EP stimulates differentiation of Treg in
culture.
DISCUSSION
EP exerted specific effect on the regulatory arm of the
immune response and thus prevented the development of
T1D in C57BL/6 mice. It promoted tolDC within the
pancreas and influenced Treg biology at multiple levels:
through the stimulation of Treg proliferation and de novo
differentiation, through the increase of CTLA-4, TGF-β, and
IL-10 expression, making them more suppressive, and through
favoring their migration to and retention at the site of
inflammation.
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FIGURE 8 | Activation and phenotype of Treg and effector T cells. The proportion of activated (CD44+), T-bet+, and RORγT+ cells within Treg (CD4+CD25high)
(A,C,E) or within effector T population (CD4+CD25med) (B,D,F) was determined in PLN or infiltrates by flow cytometry. Representative dot plots are shown on the right
hand side. Cells were first gated on live CD4+, followed by the gate on T-bet+ in CD4+CD25med or CD4+CD25high population. All measurements were performed
on samples from 7 animals per group. *p < 0.05 represents a statistically significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
The β-cell death in the investigated mouse model of T1D
occurs through the induction of oxidative stress by the action of
streptozotocin (21). Since EP possesses anti-oxidant properties,
to avoid possible false results due to interference of EP with
streptozotocin, the application of these two chemicals was at
least 3 h apart. β-cells are extremely sensitive to oxidative damage
since they have low levels of protective anti-oxidant enzymes
(22). When endangered, β-cells express alarmins. One of those is
HMGB1, whose level in β-cells of NOD mice correlates with the
initiation of T1D (15). Higher HMGB1 expression was also found
in β-cells of C57BL/6 mice treated with streptozotocin. EP is
usually characterized as an HMGB1 inhibitor and it undoubtedly
did reduce HMGB1 presence in pancreatic β-cells. Aside from
acting as an alarmin, HMGB1 might be detrimental to β-cells
because it can induce ROS generation through the stimulation of
NADPH oxidase (4). Therefore, its reduction in β-cells may have
helped protect β-cells from ROS-induced apoptosis. Surprisingly,
EP did not prevent ROS and RNI generation in phagocytic
immune cells that entered the pancreas, suggesting that this
function of antigen-presenting cells is resistant to EP’s influence.
After the initial ROS and RNI-mediated β-cell destruction
after streptozotocin treatment, immune cells infiltrate the
pancreatic islets. Subsequent β-cell apoptosis then becomes a
result of a fulminant inflammatory process. In addition to anti-
oxidant properties, EP can block inflammation as well. EP was
found effective in several animal models of diseases with a strong
inflammatory component, for example experimental colitis and
encephalomyelitis (8, 10, 11). Although little is known about
EP’s molecular targets in immune cells, its anti-inflammatory
properties are again related to the down-regulation of HMGB1
in non-immune cells. When secreted, HMGB1 can bind cell-
surface receptors for advanced glycation end products (RAGE)
and in that way intensify inflammation through generation or
propagation of cells of innate and adaptive immunity. Another
way of a pro-inflammatory HMGB1 effect could be the activation
of TLR4. For example, elevated HMGB1 expression in β-cells of
NOD mice is detected by the surface TLR4 (15). This activation
of TLR4 can trigger NF-κB signal transduction, leading to the
expression of pro-inflammatory cytokines and the up-regulation
of leukocyte adhesion molecules, thereby promoting injury and
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FIGURE 9 | In vitro effect of EP on Th cell differentiation. (A) The proportion of Th1 (CD4+ IFN-γ+), Th17 (CD4+ IL-17+), and Treg (CD4+CD25highFoxP3+) cells after
96 h of incubation of CD4+CD25− cells with adequate stimulation (described in Material and methods) and in the presence of EP (125µM), added 24 h after the start
of cell cultivation. Representative dot plots are shown. Cells were first gated on live CD4+, followed by the gate on IFN-γ+, IL-17+ or CD25highFoxpP3+. (B) The
proportion of Treg that expressed GITR, CTLA-4, and PD-1, determined by flow cytometry. Representative dot plots show the first gate on live CTLA-4+, GITR+ or
PD-1+ population, followed by the gate on CD4+CD25high. (C) The proportion of Treg after incomplete stimulation (anti-CD3+anti-CD28+IL-2) after 5 days of
incubation of CD4+ cells in the presence or absence of EP. Representative dot plots show the first gate on live CD4+ cells, followed by the gate on CD25highFoxpP3+.
(D) IL-10 concentration in supernatants of EP-treated CD4+ cells in the presence of complete Treg stimulation (anti-CD3/anti-CD28+IL-2+TGF-β), after 5 days of
incubation, measured by ELISA. *p < 0.05 represents a statistically significant difference between cells of MLDS+EP compared to those of MLDS-treated mice.
inflammation (23, 24). Consistent with these literature data, the
other reason for the preservation of β-cell function after EP
treatment was a lower degree of immune cell infiltration into
the pancreatic islets (as determined by the insulitis scoring).
Although the composition of these infiltrates was more or
less the same regarding both cells of the innate and adaptive
immunity, twomajor differences between EP-treated and diabetic
mice have been observed. One is the higher presence of tolDC,
and the other is the increased proportion of Treg. It was
already shown that secreted HMGB1 stimulates dendritic cell
maturation and in vivo homing to lymph nodes (25). So, the
observed stimulating effect of EP on the differentiation of
tolDC might be conducted through the inhibition of HMGB1
secretion. This was also confirmed in vitro where EP contributed
immensely to the differentiation of tolDC from bone marrow
precursors (personal communication—unpublished data). The
higher presence of tolDC in the pancreatic infiltrates may not
be due to de novo differentiation of immature DC, as these
cells may come from pancreatic lymph nodes where we detected
a lower number of tolDC. Additionally, despite the fact that
HMGB1 stimulates the differentiation of M1 macrophages, its
inhibition by EP did not affect the ratio between M1 and M2
macrophages.
In the inflammatory setting during T1D progression, EP
increased the number and the quality of Treg. The higher
proportion of Treg could be a result of either enhanced
proliferation or de novo differentiation. Proliferation of Treg was
confirmed in the pancreatic islets, while for their differentiation
we have only circumstantial evidence. For example, the level
of TGF-β+ (non-Treg) cells was increased after EP treatment,
suggesting that this TGF-β could drive new differentiation. Also,
EP stimulated Treg differentiation in vitro in the circumstances
of suboptimal stimulation (in the absence of TGF-β), suggesting
that EP might trigger the same signaling pathways as TGF-β
in naïve CD4+ lymphocytes. EP also enhanced the suppressive
properties of Treg in vivo. It is already known that HMGB1
inhibits Treg function by down-regulating the costimulatory
molecule CTLA-4, the Treg cell transcription factor Foxp3, and
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FIGURE 10 | Proposed mechanism of EP’s beneficial effect in T1D. EP enhances the regulatory arm of the immune response during T1D pathogenesis. From
pancreatic lymph nodes, tolDC (CD11c+CD11b−CD103+) migrate into the pancreatic islets and their proportion becomes significantly higher. Also, Treg
(CD4+CD25high) in the pancreatic lymph nodes increase their suppressive properties (CTLA-4, IL-10, and TGF-β) and migrate into the inflamed pancreatic islet
(increased CD11a and CD62L expression and proportion of CXCR3+). In the islet, since Treg are already activated (CD44+), they proliferate (Ki67+), and are retained
at the site (CD103+). Also, some of Treg express T-bet (increased proportion after EP treatment) and thereby inhibit T-bet+ effector cells (CD25med) within the PLN
and pancreatic infiltrates. Finally, EP may stimulate in vitro and in vivo differentiation of Treg through enhancement of TGF-β production. All these events result in the
preservation of β-cell function (insulin production) and reduction of HMGB1 expression.
the Treg suppressor cytokine IL-10 (26). Therefore, our results
with in vitro and in vivo EP application strongly correlate
with the observed inhibition of HMGB1 in vivo after EP
treatment. More precisely, EP increased the expression of CTLA-
4, which through binding to CD80 and/or CD86 probably
suppressed the activation of antigen-presenting cells (27). Also,
EP increased the proportion of TGF-β+ and IL-10+ Treg
and thereby significantly up-regulated their immunosuppressive
properties, as shown by their potency in the inhibition of
T effector cell proliferation. These Treg that proliferated in
response to EP treatment were probably the so-called induced
or peripheral Treg, due to their strict necessity for exogenous
lipids and pyruvate which they utilize in the Krebs cycle to
acquire energy [reviewed in (28)]. Therefore, the addition of the
stable form of pyruvate may have aided the differentiation and
proliferation of peripheral Treg through a metabolic pathway as
well.
Although the proportion of Treg was higher in both
pancreatic lymph nodes and infiltrates examined after EP
treatment, their migration to the pancreatic islets might be
significantly increased if we take into account their ex vivo
behavior in the transmigration assay. Ex vivo isolated Treg
from EP-treated mice were attracted more efficiently to the
pancreatic islets or to a CXCL12 chemokine gradient compared
to the Treg from diabetic mice. Furthermore, they expressed
higher levels of CXCR3, a chemokine receptor that responds
to CXCL9, CXCL10, and CXCL11 and guides the cells to
the site of inflammation (29), in this case the pancreatic
islet where they are successfully retained (judged by CD103
expression). The expression of CXCR5 on CD25high cells
(presumably regulatory follicular T cells) was the same in
both diabetic and EP-treated mice, suggesting that EP did not
specifically direct Treg to the germinal centers of pancreatic
lymph nodes where they can help the differentiation of
Breg (30). This result was corroborated by equal levels of
Breg found in lymph nodes and infiltrates in mice of both
groups.
It is a general opinion that Treg express signature
transcription factors of pro-inflammatory cell subsets, thereby
increasing their specificity for suppressing those particular
Th subsets. Treatment with EP increased the proportion of
T-bet+ Treg (T-bet+CD25high) in the pancreatic infiltrates and
simultaneously reduced the proportion of T-bet activated T cells
(T-bet+CD25med). However, there is a discrepancy between
this result and the equal levels of Th1 cells observed in diabetic
and EP-treated mice. This might stem from the fact that CD8+
cells may express CD25 and T-bet as well (31). Although the
inhibition of HMGB1 can theoretically interfere with Th17
polarization (32, 33), our results indicate that HMGB1 reduction
by the action of EP did not result in the down-regulation of Th17
response, which was corroborated by the equal levels of both
activated effector RORγT+CD25med cells and RORγT+ Treg
after EP treatment.
In conclusion, this study proves the beneficial role of
EP in the treatment of mouse T1D. It seems that EP
favors the activation of the regulatory arm of the immune
response and enhances its immunosuppressive properties
(Figure 10). However, the question about EP’s influence on
the Treg metabolism still remains and should be explored
as well.
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Figure S1 | Negative staining for insulin (A) and HMGB1 (B).
Figure S2 | The effect of EP on innate cells proportion and function. (A) F4/80+
cell proportion within the spleen and the pancreatic infiltrates. Representative dot
plots for the spleen are shown on the right hand side. (B) The proportion of M1
(F4/80+CD40+) and M2 (F4/80+CD206+) macrophages within the pancreatic
infiltrates, with representative dot plots below. (C) The intracellular production of
nitric oxide (NO) measured by DAF-FM mean fluorescence intensity (MFI) and
reactive oxygen species (ROS) measured by DHR MFI within the pancreatic
infiltrates, along with representative histograms. (D) The proportion of MHC class
II+ antigen-presenting cells with co-stimulatory molecules CD80+ or CD86+
within pancreatic infiltrates, along with representative dot plots.
Figure S3 | Phenotypic analysis of adaptive immune cells after EP treatment.
Representative dot plots of the proportion of cytotoxic lymphocytes (CD8+) or B
lymphocytes (B220+ or CD19+) in spleen (A), PLN (B) or pancreatic infiltrates
(C). Representative dot plots of the proportion of regulatory B cells
(CD19+CD5+ IL-10+) within PLN (D) and pancreatic infiltrates (E) (first gated on
live IL-10+ cells, followed by the gate on CD19+CD5+). (F) Representative dot
plots of the proportion of activated cytotoxic lymphocytes (CD8+CD44+) in the
pancreatic infiltrates.
Figure S4 | Phenotypic analysis of adaptive immune cells after EP treatment.
Representative dot plots of the proportion of Th (CD4+) and Th1 (CD4+ IFN-γ+),
Th2 (CD4+ IL-4+) and Th17 (CD4+ IL-17+) within the spleen (A), PLN (B) and
pancreatic infiltrates (C) of MLDS or MLDS+EP-treated mice (first gated on live
CD4+ cells, followed by the gate on IFN–γ+, IL-4+, or IL-17+).
Figure S5 | Characterization of Treg after EP treatment. (A) The expression of
FoxP3, GITR, PD-1, and CD101 within CD4+CD25high measured by mean
fluorescence intensity (MFI), along with representative histograms.
Figure S6 | The effect of EP on Treg migratory abilities. (A) The proportion of
CXCR5+ cells within activated Th cells (CD4+CD25med) or within Treg
(CD4+CD25high) from PLN. Representative dot plots show the first gate on either
live CD4+CD25med or live CD4+CD25high cells, followed by the gate on
CXCR5+. (B) Representative dot plots for CD25highCD103+ proportion within
PLN.
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